Latest Breaking News On - Biofrontera pharma gmbh - Page 1 : vimarsana.com

Form 8-K Biofrontera Inc. For: Feb 13

Biofrontera : Notes to the Consolidated Financial Statements - Form 8-K -October 03, 2023 at 05:27 pm EDT

Notes to the Consolidated Financial Statements F-7 F-1 ...

Form 424B3 Biofrontera Inc.

Biofrontera Shares Retreat 7% After Wednesday's Big Move Higher

Biofrontera Inc. Announces FDA Approval of Biofrontera

Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera...

Biofrontera Shares Jump 31% After FDA Approves Contract Laboratory for Ameluz

Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz

13.04.2022 - Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of ... Seite 1

Biofrontera Inc. (BFRI) Reports FDA Orange Book Listing of U.S. Patent for BF-RhodoLED XL, Extends Protection of Ameluz-PDT Through October 2040

Sun Pharma arm DUSA to get $22.5 mn from Biofrontera for settlement of litigation

Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland

Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG, and Medac signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland. Under the terms of the agreement, Medac will make an immediate one-time upfront payment of EUR 50,000 to the Company, plus an additional one-time payment of EUR 150,000 following receipt of the drug’s reimbursement eligibility from the Polish health insurance providers. According to the agreement, Medac receives exclusive distribution rights for Poland. Once reimbursement eligibility has been granted in Poland, Biofrontera will supply Ameluz® to Medac at a fixed transfer price based on the expected net revenues.